Cyrille Buisset1, Carole Guerin2, Pierre-Julien Cungi3, Mickael Gardette4, Nunzia-Cinzia Paladino2, David Taïeb5, Thomas Cuny6, Frederic Castinetti6, Frederic Sebag2. 1. Department of Digestive, Hepato-Biliary and Endocrine Surgery, University Hospital of Nancy, Vandoeuvre-les-Nancy, France. cyrille.buisset@gmail.com. 2. Department of Endocrine Surgery, Aix-Marseille University, La Conception University Hospital, Marseille, France. 3. Department of Anesthesia, Sainte Anne Military Teaching Hospital, Toulon, France. 4. Department of Anesthesia, Aix-Marseille University, La Conception University Hospital, Marseille, France. 5. Department of Nuclear Medicine, Aix-Marseille University, La Conception University Hospital, Marseille, France. 6. Department of Endocrinology, Aix-Marseille University, Marseille Medical Genetics, INSERM, La Conception University Hospital, Marseille, France.
Abstract
BACKGROUND: Despite significant advances in imaging and genetics, as well as surgical and anesthetic innovations, morbidity in pheochromocytoma surgery remains significant. The aim of this study was to identify the predictive factors of global and cardiovascular morbidity following unilateral laparoscopic adrenalectomy for pheochromocytoma. METHODS: We conducted a retrospective study from a unicentric cohort. All patients who underwent non-converted laparoscopic unilateral adrenalectomy for pheochromocytoma between 2000 and 2017 were included. Our patients did not systematically benefit from preoperative pharmacological preparation. It is to be noted that they never received alpha-blockers. Preoperative, intraoperative, and postoperative data during follow-ups were collected. Univariate and multivariate analyses by logistic regression were performed. RESULTS: A total of 134 patients were included. Fifty-three percent of patients did not receive preoperative pharmacological preparation (PPP) and 33% neither preoperative antihypertensives nor PPP before surgery. There was no postoperative mortality. The global morbidity was 13.4%, while cardiovascular morbidity was 4.5%. The main factors associated with global morbidity were preoperative diuretics, a medical history of stroke, and the need for pressor amines postoperatively. The main factor associated with cardiovascular morbidity was the need for pressor amines postoperatively. Predictive factors of postoperative need for pressor amines for hypotension were the tumor size, preoperative beta-blockers, and/or diuretics. CONCLUSION: In this large cohort of patients, our data revealed no mortality and low global and cardiovascular morbidity rates, showing that pheochromocytoma surgery without systematic PPP and even without preoperative antihypertensives is feasible and safe for selected patients. Our data also highlight the need for a good preoperative evaluation of the patient and the tumor, in order to optimize treatments and to help the detection of high-risk patients. This also allows us to better prevent and anticipate their possible complications.
BACKGROUND: Despite significant advances in imaging and genetics, as well as surgical and anesthetic innovations, morbidity in pheochromocytoma surgery remains significant. The aim of this study was to identify the predictive factors of global and cardiovascular morbidity following unilateral laparoscopic adrenalectomy for pheochromocytoma. METHODS: We conducted a retrospective study from a unicentric cohort. All patients who underwent non-converted laparoscopic unilateral adrenalectomy for pheochromocytoma between 2000 and 2017 were included. Our patients did not systematically benefit from preoperative pharmacological preparation. It is to be noted that they never received alpha-blockers. Preoperative, intraoperative, and postoperative data during follow-ups were collected. Univariate and multivariate analyses by logistic regression were performed. RESULTS: A total of 134 patients were included. Fifty-three percent of patients did not receive preoperative pharmacological preparation (PPP) and 33% neither preoperative antihypertensives nor PPP before surgery. There was no postoperative mortality. The global morbidity was 13.4%, while cardiovascular morbidity was 4.5%. The main factors associated with global morbidity were preoperative diuretics, a medical history of stroke, and the need for pressor amines postoperatively. The main factor associated with cardiovascular morbidity was the need for pressor amines postoperatively. Predictive factors of postoperative need for pressor amines for hypotension were the tumor size, preoperative beta-blockers, and/or diuretics. CONCLUSION: In this large cohort of patients, our data revealed no mortality and low global and cardiovascular morbidity rates, showing that pheochromocytoma surgery without systematic PPP and even without preoperative antihypertensives is feasible and safe for selected patients. Our data also highlight the need for a good preoperative evaluation of the patient and the tumor, in order to optimize treatments and to help the detection of high-risk patients. This also allows us to better prevent and anticipate their possible complications.
Entities:
Keywords:
Alpha-blockers; Laparoscopic adrenalectomy; Morbidity; Pheochromocytoma; Preoperative pharmacological preparation; Surgery
Authors: Laurent Brunaud; Phi-Linh Nguyen-Thi; Eric Mirallie; Marco Raffaelli; Menno Vriens; Pierre-Etienne Theveniaud; Myriam Boutami; Brendan M Finnerty; Wessel M C M Vorselaars; Inne Borel Rinkes; Rocco Bellantone; Celestino Lombardi; Thomas Fahey; Rasa Zarnegar; Laurent Bresler Journal: Surg Endosc Date: 2015-06-20 Impact factor: 4.584
Authors: M Lafont; C Fagour; M Haissaguerre; G Darancette; T Wagner; J B Corcuff; A Tabarin Journal: J Clin Endocrinol Metab Date: 2014-11-18 Impact factor: 5.958
Authors: M A Kinney; M E Warner; J A vanHeerden; T T Horlocker; W F Young; D R Schroeder; P M Maxson; M A Warner Journal: Anesth Analg Date: 2000-11 Impact factor: 5.108
Authors: Kent W Kercher; Yuri W Novitsky; Adrian Park; Brent D Matthews; Demetrius E M Litwin; B Todd Heniford Journal: Ann Surg Date: 2005-06 Impact factor: 12.969
Authors: H Bruynzeel; R A Feelders; T H N Groenland; A H van den Meiracker; C H J van Eijck; J F Lange; W W de Herder; G Kazemier Journal: J Clin Endocrinol Metab Date: 2009-12-04 Impact factor: 5.958
Authors: Jennifer Bryant; Jennifer Farmer; Lisa J Kessler; Raymond R Townsend; Katherine L Nathanson Journal: J Natl Cancer Inst Date: 2003-08-20 Impact factor: 13.506
Authors: Thomas Uslar; Ignacio F San Francisco; Roberto Olmos; Stefano Macchiavelo; Alvaro Zuñiga; Pablo Rojas; Marcelo Garrido; Alvaro Huete; Gonzalo P Mendez; Ignacio Cortinez; José Tomás Zemelman; Joaquín Cifuentes; Fernando Castro; Daniela Olivari; José Miguel Domínguez; Eugenio Arteaga; Carlos E Fardella; Gloria Valdés; Rodrigo Tagle; Rene Baudrand Journal: J Endocr Soc Date: 2021-04-22
Authors: Marta Araujo-Castro; Rogelio García Centero; María-Carmen López-García; Cristina Álvarez Escolá; María Calatayud Gutiérrez; Concepción Blanco Carrera; Paz De Miguel Novoa; Nuria Valdés Gallego; Felicia A Hanzu; Paola Gracia Gimeno; Mariana Tomé Fernández-Ladreda; Juan Carlos Percovich Hualpa; Mireia Mora Porta; Javier Lorca Álvaro; Héctor Pian; Ignacio Ruz Caracuel; Alfonso Sanjuanbenito Dehesa; Victoria Gómez Dos Santos; Ana Serrano Romero; Cristina Lamas Oliveira Journal: Endocrine Date: 2021-08-09 Impact factor: 3.633